ASCO 2023: Keytruda becomes a new option in perioperative NSCLC  

Early-stage non-small cell lung cancer (NSCLC) is typically treated with surgery followed by adjuvant therapy (chemo ± radiation) in patients …

Eikon Therapeutics bag $106m to fund eager acquisitions

San Francisco-based biotech Eikon Therapeutics has made waves in the bay after managing to raise $106m in its Series C …

Coherus allies with Mark Cuban to challenge AbbVie for Humira biosimilar

In a bit to challenge the market dominance of AbbVie’s Humira (adalimumab), the online pharmacy Cost Plus Drugs, owned by …

CMS mandates registry data for coverage of Alzheimer’s drugs

The Centers for Medicare and Medicaid Services’ (CMS) Administrator Chiquita Brooks-LaSure announced that Eisai’s Leqembi (lecanemab) will be covered under …

Novartis touts breast cancer win with “landmark” Kisqali results

Kicking off this year's American Society of Clinical Oncology's (ASCO) conference, Novartis has released data supporting the use of its …